Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Study for Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Therapy in Japan

NCT04509622 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04509622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04509622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Study for Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Therapy in Japan
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
October 5, 2020
Completion date
April 15, 2021
Enrollment
14 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)